Claim Missing Document
Check
Articles

Found 3 Documents
Search

Komplikasi pada Kehamilan dengan Riwayat Caesarian Section Arli Suryawinata; Nurul Islamy
Jurnal Agromedicine Unila: Jurnal Kesehatan dan Agromedicine Vol. 6 No. 2 (2019): Jurnal Kesehatan dan Agromedicine
Publisher : Fakultas Kedokteran Universitas Lampung

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Beberapa tahun terakhir pilihan melahirkan dengan operasi Caesarian Section (CS) cenderung meningkat baik di negara maju ataupun di negara berkembang. Tindakan CS seharusnya hanya menjadi pilihan bagi tenaga medis dengan indikasi menyelamatkan ibu dan janin. Indikasi sosial menjadi salah satu alasan terbesar di banyak negara untuk melakukantindakan CS. Hal ini tentu membutuhkan perhatian khusus mengingat ibu dengan riwayat CS cenderung memiliki resiko kejadian komplikasi pada kehamilan berikutnya. Kehamilan dengan riwayat CS memiliki resiko lebih tinggi untuk mengalami berbagai komplikasi. Kejadian komplikasi pada kehamilan dengan riwayat CS berkaitan dengan terbentuknya jaringan parut uterus. Luka bekas CS akan mengalami perubahan selama proses kehamilan selanjutnya dimana bekas luka akan menipiskan daerah sekitar diikuti pelebaran bekas luka tersebut akibat adanya regangan. Hal ini membuat daerah SBR pada kehamilan dengan riwayat CS akan menjadi lebih tipis. Perubahan yang terjadi tersebut menjadi dasar bagaimana komplikasi seperti ruptur uteri, plasenta previa, plasenta akreta dan abruptio plasenta terjadi. Akan tetapi hal tersebut tidak menghilangkan kemungkinan untuk melakukan persalinan pervaginam pada ibu dengan riwayat CS. Persalinan Pervaginan pada Pasien Pernah Seksio Sesarea (P4S) memberikan keuntungan terkait angka morbiditas yang lebih rendah dan lama perawatan yang lebih singkat dibandingkan dengan pemilihan CS kembali. Kehamilan dengan riwayat CSmerupakan kehamilan dengan risiko tinggi sehinggga memerlukan pengawasan dan penatalaksaan khusus. Persalinan pada ibu dengan riwayat CS dapat dilakukan dengan dua cara yaitu perabdominam yaitu CS elektif atau percobaan persalinan pervaginam pada bekas CS (TOLAC).Kata kunci: Kehamilan, Caesarian Section, P4S, TOLAC
Evaluating the Indigenous Probiotic Lactococcus lactis D4 as an Adjuvant to Capecitabine: Modulation of NF-κB in a Colorectal Carcinogenesis Model Arli Suryawinata; M Iqbal Rivai; Rini Suswita; Irwan; Avit Suchitra; Raflis Rustam
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 10 No. 5 (2026): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v10i5.1572

Abstract

Background: Chronic inflammation driven by the nuclear factor kappa-B (NF-κB) signaling pathway is a fundamental driver of colorectal cancer (CRC) pathogenesis, promoting tumor survival, mucosal proliferation, and profound chemoresistance. Capecitabine is a standard first-line fluoropyrimidine chemotherapy; however, its clinical utility is frequently compromised by dose-limiting toxicities and the activation of inflammatory feedback loops. Lactococcus lactis D4, a novel probiotic strain isolated from traditional Indonesian fermented buffalo milk (dadih), possesses well-documented immunomodulatory properties. Methods: A randomized controlled experimental study was conducted utilizing male Sprague-Dawley rats (n=37). Colorectal carcinogenesis was chemically induced via intraperitoneal administration of 1,2-dimethylhydrazine (DMH). Following strict histopathological confirmation of malignancy, the cohort was randomized into five distinct groups: Negative Control, Positive Control, L. lactis D4 monotherapy, Capecitabine monotherapy, and Combination therapy. Interventions were administered daily for 14 days. Outcomes included NF-κB protein expression assessed via immunohistochemistry (IHC) and targeted gene expression quantification via RT-qPCR. Results: Immunohistochemical analysis demonstrated that the positive control group exhibited significantly elevated NF-κB protein expression (35.87 ± 13.53%). Capecitabine monotherapy significantly reduced this expression to 16.07 ± 3.79% (p=0.003). The Combination therapy achieved a profound reduction in NF-κB protein expression down to 12.99 ± 4.92%; however, this was not statistically superior to Capecitabine alone (p=1.000). Conversely, RT-qPCR analysis revealed no statistically significant difference in NF-κB mRNA levels among the experimental groups (p=0.094). Conclusion: The combination of L. lactis D4 and Capecitabine effectively reduces NF-κB protein expression in a preclinical CRC model, achieving suppression levels comparable to primary chemotherapy. The distinct discordance between the significant protein suppression and the sustained mRNA expression levels suggests potential post-transcriptional or post-translational regulatory mechanisms that warrant further targeted molecular investigation.
Evaluating the Indigenous Probiotic Lactococcus lactis D4 as an Adjuvant to Capecitabine: Modulation of NF-κB in a Colorectal Carcinogenesis Model Arli Suryawinata; M Iqbal Rivai; Rini Suswita; Irwan; Avit Suchitra; Raflis Rustam
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 10 No. 5 (2026): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v10i5.1572

Abstract

Background: Chronic inflammation driven by the nuclear factor kappa-B (NF-κB) signaling pathway is a fundamental driver of colorectal cancer (CRC) pathogenesis, promoting tumor survival, mucosal proliferation, and profound chemoresistance. Capecitabine is a standard first-line fluoropyrimidine chemotherapy; however, its clinical utility is frequently compromised by dose-limiting toxicities and the activation of inflammatory feedback loops. Lactococcus lactis D4, a novel probiotic strain isolated from traditional Indonesian fermented buffalo milk (dadih), possesses well-documented immunomodulatory properties. Methods: A randomized controlled experimental study was conducted utilizing male Sprague-Dawley rats (n=37). Colorectal carcinogenesis was chemically induced via intraperitoneal administration of 1,2-dimethylhydrazine (DMH). Following strict histopathological confirmation of malignancy, the cohort was randomized into five distinct groups: Negative Control, Positive Control, L. lactis D4 monotherapy, Capecitabine monotherapy, and Combination therapy. Interventions were administered daily for 14 days. Outcomes included NF-κB protein expression assessed via immunohistochemistry (IHC) and targeted gene expression quantification via RT-qPCR. Results: Immunohistochemical analysis demonstrated that the positive control group exhibited significantly elevated NF-κB protein expression (35.87 ± 13.53%). Capecitabine monotherapy significantly reduced this expression to 16.07 ± 3.79% (p=0.003). The Combination therapy achieved a profound reduction in NF-κB protein expression down to 12.99 ± 4.92%; however, this was not statistically superior to Capecitabine alone (p=1.000). Conversely, RT-qPCR analysis revealed no statistically significant difference in NF-κB mRNA levels among the experimental groups (p=0.094). Conclusion: The combination of L. lactis D4 and Capecitabine effectively reduces NF-κB protein expression in a preclinical CRC model, achieving suppression levels comparable to primary chemotherapy. The distinct discordance between the significant protein suppression and the sustained mRNA expression levels suggests potential post-transcriptional or post-translational regulatory mechanisms that warrant further targeted molecular investigation.